Parlux first quarter
This article was originally published in The Rose Sheet
Executive Summary
Net sales advance 10% to $19.8 mil. for the period ended June 30 and company recorded $1.1 mil. in net income, compared to loss of $1.7 mil. in prior-year period. The 2001 quarter was negatively impacted by a $2.9 mil. charge for an unrealized loss on an investment. Excluding the charge, net income rose 22% in the recent quarter. Parlux gearing up for launches of Perry Man and Perry Woman fragrances as extensions of firm's Perry Ellis designer portfolio (1"The Rose Sheet" April 15, 2002, p. 6)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.